BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach

被引：1

作者：

Menger, Jenna M. ^{[1
]}

Sathianathen, Ryan S. ^{[2
]}

Sakamoto, Kathleen M. ^{[3
]}

Hijiya, Nobuko ^{[1
]}

机构：

[1] Columbia Univ, Dept Pediat, Div Pediat Hematol Oncol Stem Cell Transplant, Irving Med Ctr, New York, NY 10069 USA

[2] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA

[3] Stanford Univ, Dept Pediat, Div Hematol Oncol, Stanford, CA 94305 USA

来源：

CURRENT ONCOLOGY REPORTS | 2024年 / 26卷 / 03期

关键词：

Pediatric cancer; Chronic myeloid leukemia; CML; Tyrosine kinase inhibitor; TKI; BCR-ABL1; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE INHIBITORS; OMACETAXINE MEPESUCCINATE; IMATINIB; PHASE; SURVIVAL; THERAPY; CML; DASATINIB; NILOTINIB;

D O I：

10.1007/s11912-024-01502-z

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of ReviewThe purpose of this review is to summarize the most updated treatment recommendations for pediatric CML, and to discuss current areas of investigation.Recent FindingsThere is new phase 1 data to support the safety of the non-ATP competitive tyrosine kinase inhibitor (TKI) asciminib in the pediatric cohort. Ongoing studies are investigating the role of treatment-free remission in children.SummaryChronic phase CML in children is managed with lifelong TKI therapy; however, evidence of deeper remissions sustained with second-generation TKIs may permit shorter treatment courses. Use of more specific TKIs may mitigate some of the side effects specific to the pediatric cohort. Children with advanced phase CML should achieve a complete hematologic remission with use of a second-generation TKI prior to transplant to achieve the best outcome.

引用

页码：250 / 257

页数：8

共 50 条

[1] BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach
Jenna M. Menger
Ryan S. Sathianathen
Kathleen M. Sakamoto
Nobuko Hijiya
Current Oncology Reports, 2024, 26 : 250 - 257
[2] Dendritic cells for vaccination in BCR/ABL-positive chronic myeloid leukemia.
Westermann, J
Kopp, J
Körner, I
Döhner, C
Döhner, H
Mohm, O
Ehninger, G
Richter, G
Dörken, B
Pezzutto, A
BLOOD, 2000, 96 (11) : 144A - 144A
[3] Coincidence of bcr/abl-positive chronic myeloid leukemia and bcr/abl-negative chronic myelopioliferative disorder and its relevance to the course of disease
Buesche, Guntram
Bock, Oliver
Hussein, Kais
von Neuhoff, Nils
Schlegelberger, Brigitte
Kreipe, Hans H.
BLOOD, 2007, 110 (11) : 867A - 867A
[4] ABL gene fuses BCR during t(20;22) results in Philadelphia-negative, but BCR/ABL-positive chronic myeloid leukemia
Y Ito
T Shimamoto
Y Kuriyama
A Nakajima
M Sumi
Y Watanabe
H Beppu
K Ohtsubo
K Ohyashiki
Leukemia, 2002, 16 : 951 - 952
[5] ABL gene fuses BCR during t(20;22) results in Philadelphia-negative, but BCR/ABL-positive chronic myeloid leukemia
Ito, Y
Shimamoto, T
Kuriyama, Y
Nakajima, A
Sumi, M
Watanabe, Y
Beppu, H
Ohtsubo, K
LEUKEMIA, 2002, 16 (05) : 951 - 952
[6] Transgenic mouse models of BCR/ABL-positive chronic myelogenous leukemia: A review
Inokuchi, K
CURRENT GENOMICS, 2005, 6 (02) : 89 - 95
[7] NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR–ABL-positive mice
C I-U Chen
S Koschmieder
L Kerstiens
M Schemionek
B Altvater
S Pscherer
J Gerss
H T Maecker
W E Berdel
H Juergens
P P Lee
C Rossig
Leukemia, 2012, 26 : 465 - 474
[8] De Novo BCR/ABL-Positive Acute Myeloid Leukemia: Report of Two Cases and Review of the Literature
Vora, Moiz
Wei, Eric
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 149 : S69 - S70
[9] Dendritic cells vaccination in BCR/ABL-positive chronic myeloid leukemia -: Final results of a phase I/II study.
Westermann, J
Kopp, J
van Lessen, A
Hecker, A
Baskaynak, G
Le Coutre, P
Döhner, C
Döhner, H
Dörken, B
Pezzutto, A
BLOOD, 2004, 104 (11) : 802A - 802A
[10] Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
F Fei
S Stoddart
M Müschen
Y-m Kim
J Groffen
N Heisterkamp
Leukemia, 2010, 24 : 813 - 820

← 1 2 3 4 5 →